We would love to hear your thoughts about our site and services, please take our survey here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksTILS.L Share News (TILS)

  • There is currently no data for TILS

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

WINNERS & LOSERS SUMMARY: Future Rises After Positive Annual Outlook

Mon, 01st Jul 2019 10:49

(Alliance News) - The following stocks are the leading risers and fallers within the main London indices on Monday.----------FTSE 100 - WINNERS----------DS Smith, up 1.7%. The paper and packaging firm said it completed the sale of two packaging businesses in north west France and in Portugal to Memphis, Tennessee-based peer International Paper for EUR63 million. DS Smith said the sale honours the commitment made to the European Commission in relation to the clearance of its acquisition of Spanish packaging firm Europac, which completed in January. Last month, DS Smith had said financial 2019, which ended on April 30, was a "year of good delivery" overall, with "substantial" progress being made overseas and the integration of Europac was going well. Fellow packaging firms Smurfit Kappa and Mondi were up 2.6% and 1.7%, respectively. ----------FTSE 100 - LOSERS----------Fresnillo, down 2.9%. The Mexican gold miner was tracking spot gold prices lower, quoted at USD1,390.28 an ounce, down sharply from USD1,411.62 late Friday. Last week, gold had touched a six-year high of USD1,438.63. Additionally, Fresnillo on Monday said it has decided to align tax treatment for all of the company's underground mining operations, resulting in a USD8.0 million impact on profit for the six months to June-end. Shares in midcap gold miners Centamin and Hochschild Mining also were being hurt by the lower gold price, down 2.2% and 1.7%, respectively.----------International Consolidated Airlines Group, down 1.2%. Bernstein downgraded the airlines operator to Market Perform from Outperform. ----------FTSE 250 - WINNERS----------Future, up 9.0%. The digital media and publishing firm said full-year results will be ahead of expectations, underpinned by good audience growth within the Media division and the continued strong performance of recent acquisitions. The guidance was also attributed to a continuation of positive trends seen in the first half. Future's financial year ends September and will report annual results in November. "Future has a platform which enables it to monetise specialist content through a mixture of e-commerce, getting content users to click through to partnered retailers, events and online advertising. The plan is to feed newly-acquired assets into this platform. Newspaper and magazine publishers continue to battle falling sales and have struggled to get readers to pay for their relatively generic content, but consumers have shown a greater willingness to pay for specialist and niche content which they are unable to get elsewhere," said AJ Bell's Russ Mould.----------FTSE 250 - LOSERS----------John Laing Group, down 1.0%. Barclays started coverage on the infrastructure project investor at Equal Weight. ----------OTHER MAIN MARKET AND AIM - WINNERS----------Tiziana Life Sciences, up 14%. The biotechnology company noted a study in which a drug similar to Foralumab was shown to delay the onset of type-1 diabetes. The phase two study of Teplizumab, an anti-CD3 antibody similar to Foralumab being developed by Provention Bio, was published in the New England Journal of Medicine. Type-1 diabetes is caused by the immune system's T cells attacking insulin-producing cells in the body. Anti-CD3 antibodies like Tiziana's Foralumab and Provention Bio's Teplizumab suppress the immune system to prevent this from happening. Teplizumab is derived from mice and was injected intravenously in patients whose relatives already have type 1 diabetes. Of the 76 patients evaluated, 72% were under 18. The patients were randomised to receive either a 14-day course of Teplizumab or placebo and tested at six-month intervals. At the end of the Teplizumab trial, 57% of participants treated with the drug had not developed diabetes compared to 28% on the placebo.----------OTHER MAIN MARKET AND AIM - LOSERS----------Hurricane Energy, down 17%. The oil and gas explorer said it will abandon and plug the Warwick Deep well after it did not produce at commercial rates. Hurricane had drilled the offshore North Sea well to 1,964 metres, with results indicating a 712-metre horizontal section of fractured basement reservoir. However, initial analysis suggests the well found a "poorly" connected part of the fracture network within the oil column, and the well produced at non-commercial rates. Following plugging and abandoning Warwick Deep, Hurricane will move the rig to the Lincoln Crestal wall, the second of three wells on the Greater Warwick Area.----------

More News
27 Apr 2020 09:43

Tiziana Life Sciences files for patent on potential Covid-19 therapy

(Sharecast News) - Biotechnology company Tiziana Life Sciences has filed a provisional patent application on the combination of nanoparticle-Actinomycin D (NP-ACT D) with anti-interleukin-6 receptor monoclonal antibody (anti-IL-6R), it announced on Monday, as a potential therapy for the management of Covid-19 disease.

Read more
24 Apr 2020 18:39

Tiziana Life Sciences Acquires Potential Covid-19 Treatment Medication

Tiziana Life Sciences Acquires Potential Covid-19 Treatment Medication

Read more
9 Apr 2020 11:23

UK WINNERS & LOSERS SUMMARY: Lockdowns Lift Just Eat Takeaway Orders

UK WINNERS & LOSERS SUMMARY: Lockdowns Lift Just Eat Takeaway Orders

Read more
9 Apr 2020 09:12

Tiziana Life Sciences Shares Double On Covid-19 Treatment News

Tiziana Life Sciences Shares Double On Covid-19 Treatment News

Read more
9 Apr 2020 08:03

LONDON BRIEFING: Bank Of England Extends UK Government's Overdraft

LONDON BRIEFING: Bank Of England Extends UK Government's Overdraft

Read more
16 Mar 2020 17:48

Tiziana Raises USD10 Million To Help Fund Covid-19 Drug Development

Tiziana Raises USD10 Million To Help Fund Covid-19 Drug Development

Read more
12 Mar 2020 14:31

Tiziana Secures USD10 Million To Help Coronavirus Antibody Development

Tiziana Secures USD10 Million To Help Coronavirus Antibody Development

Read more
11 Mar 2020 12:15

Tiziana Life Sciences expediting development of Covid-19 drug

(Sharecast News) - Tiziana Life Sciences said on Wednesday that it is expediting the development of a drug that could help in the treatment of people infected with Covid-19.

Read more
11 Mar 2020 10:51

Tiziana Shares Skyrocket On Expedited Covid-19 Treatment Development

Tiziana Shares Skyrocket On Expedited Covid-19 Treatment Development

Read more
17 Feb 2020 14:30

Tiziana Life Sciences Proposes ADS Offering On Nasdaq

Tiziana Life Sciences Proposes ADS Offering On Nasdaq

Read more
4 Feb 2020 13:26

DIRECTOR DEALINGS SUMMARY: Biffa Municipal MD Sells 154,000 Shares

DIRECTOR DEALINGS SUMMARY: Biffa Municipal MD Sells 154,000 Shares

Read more
21 Jan 2020 16:09

Tiziana Life Sciences Hires OKYO Pharma Director MacRae As Non-Exec

Tiziana Life Sciences Hires OKYO Pharma Director MacRae As Non-Exec

Read more
14 Jan 2020 14:42

DIRECTOR DEALINGS: Tiziana Life Says Associate Of Chair Bought Shares

DIRECTOR DEALINGS: Tiziana Life Says Associate Of Chair Bought Shares

Read more
13 Jan 2020 11:07

Tiziana Life Science To Cancel AIM Trading Ahead Of Move To Bermuda

Tiziana Life Science To Cancel AIM Trading Ahead Of Move To Bermuda

Read more
9 Jan 2020 12:21

Tiziana Says Antibody Foralumab "Well Tolerated" At All Doses Tested

Tiziana Says Antibody Foralumab "Well Tolerated" At All Doses Tested

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.